Table 1. Summary of Ongoing Clinical Trials with Anti-IL-33 Monoclonal Antibody in Asthma and COPD.

disease	patients	study design	clinicaltrials.gov identifier	phase
asthma	moderately severe patients	randomized double blind	NCT03207243	II
asthma	mild allergic asthma	randomized	NCT03112577	I
COPD	moderate to severe COPD	randomized double blind	NCT03546907	I